Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The San Francisco-based startup, which closed a $5 million Series A round in 2017, aims to develop nutritionally enhanced food and feed crops.
Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.
Cornell claims that it was fraudulently induced into settling a patent-infringement lawsuit it filed with Life Tech against Illumina.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.